Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

19.37 +3.06 (+18.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adma Biologics

< Previous 1 2 3 4 5 6 7 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
Assessing ADMA Biologics: Insights From 4 Financial Analysts
Via Benzinga
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
Expert Ratings For ADMA Biologics
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Via Benzinga
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Mad Money's Jim Cramer recommends holding on to Vertiv Holdings, which is set to report its Q2 results before the opening bell on July 24. 
Via Benzinga
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Owning millionaire-making stocks can be a life changer. Look no further than these three companies which are full of potential. 
Via InvestorPlace
Bull Run Alert: 3 Stocks Set to Soar in the Coming Months
Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.